c-Cbl interacts with CD38 and promotes retinoic acid-induced differentiation and G0 arrest of human myeloblastic leukemia cells

Cancer Research

Volumn 68, Issue 21, 2008, Pages 8761-8769

  Shen, Miaoqing ^a   Yen, Andrew ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; CD38 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; RETINOIC ACID;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL STRAIN HL 60; CONTROLLED STUDY; DOWN REGULATION; ENERGY TRANSFER; ENZYME PHOSPHORYLATION; FLUORESCENCE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; WILD TYPE;

ANTIGENS, CD38; BASE SEQUENCE; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE, TUMOR; DNA PRIMERS; FLOW CYTOMETRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; G0 PHASE; HL-60 CELLS; HUMANS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-CBL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRETINOIN;

EID: 55349137357     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1058     Document Type: Article

References (45)

1. Sklan D. Vitamin A in human nutrition. Prog Food Nut Sci 1987;11:39-55.
2. Mann G, Reinhardt D, Ritter J, et al. Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early death in children. Ann Hematol 2001;80:417-22.
3. Collins SJ, Gallo RC, Gallagher RE. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 1977;270:347-9.
4. Bretiman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A 1980;77:2926-40.
5. Yen A. HL-60 cells as a model of growth control and differentiation: the significance of variant cells. Hematol Rev 1990;4:5-46.
6. Yen A, Roberson MS, Varvayanis S, Lee AT. Retinoic acid induces mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res 1998;58:3163-72.
7. Yen A, Roberson MS, Varvayanis S. Retinoic acid selectively activates the ERK2 but not JNK/SAPK or p38 MAP kinases when inducing myeloid differentiation. In Vitro Cell Dev Biol Anim 1999;35:527-32.
8. Swaminathan G, Tsygankov A. The Cbl family proteins: ring leaders in regulation of cell signaling. J Cell Physiol 2006;209:21-43.
9. Sanjay A, Houghton A, Neff L, et al. Cbl associates with Pyk2 and Src to regulate Src kinase activity, avh3 integrin-mediated signaling, cell adhesion, and osteoclast motility. J Cell Biol 2001;152:181-95.
10. Yokouchi M, Kondo T, Houghton A, et al. Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7. J Biol Chem 1999;274:31707-12.
11. Ota S, Hazeki K, Rao N, et al. The RING finger domain of Cbl is essential for negative regulation of the Syk tyrosine kinase. J Biol Chem 2000;275:414-22.
12. Thien CBF, Langdon WY. c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signaling responses. Biochem J 2005;391:153-66.
13. Bonita DP, Miyake S, Lupher ML, Langdon WY, Band H. Phosphotyrosine binding domain-dependent upregulation of the platelet-derived growth factor receptor α signaling cascade by transforming mutants of Cbl: implications for Cbl's function and oncogenicity. Mol Cell Biol 1997;17:4597-610.
14. Meng W, Sawasdikosol S, Burakoff SJ, Eck MJ. Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70ki nase. Nature 1999;398:84-90.
15. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 1999;286:309-12.
16. Zheng N, Wang P, Jeffrey PD, Pavletich NP. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligase. Cell 2000;102:533-9.
17. Levkowitz G, Waterman H, Ettenberg SA, et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 1999;4:1029-40.
18. Szymkiswicz DI, Soubeyran P. Cbl signaling networks in the regulation of cell function. Cell Mol Life Sci 2003;60:1805-27.
19. Schmidt MH, Dikic I. The Cbl interactome and its functions. Nat Rev Mol Cell Biol 2005;6:907-19.
20. Kontani K, Kikimoto I, Nishina H, et al. Tyrosine phosphorylation of the c-Cbl proto-oncogene product mediated by cell surface antigen CD38 in HL-60 cells. J Biol Chem 1996;271:1534-7.
21. Jackson DG, Bell JI. Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J Immunol 1990;144:2811-5.
22. Albeniz I, Demir O, Turker-Sener L, Yalcintepe L, Nurten R, Bermek E. Erythrocyte CD38 as a prognostic marker in cancer. Hematology 2007;12:409-14.
23. Damle RN, Temburni S, Calissano C, et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 2007;110:3352-9.
24. March S, Graupera M, Rosa Sarrias M, et al. Identification and functional characterization of the hepatic stellate cell CD38 cell surface molecule. Am J Pathol 2007;170:176-87.
25. Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leukemia Res 2001;25:1-12.
26. Zubiaur M, Fernandez O, Ferrero E, et al. CD38 is associated with lipid rafts and upon receptor stimulation leads to Akt/Protein kinase B and Erk activation in the absence of the CD3. Immune receptor tyrosine-based activation motifs. J Biol Chem 2002;277:13-22.
27. Lamkin TJ, Chin V, Varvayanis S, et al. Retinoic acid-induced CD38 expression in HL-60 myeloblastic leukemia cells regulates cell differentiation or viability depending on expression levels. J Cell Biochem 2006;97:1328-38.
28. D'Arena G, Musto P, Cascavilla N, et al. CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2001;42:109-14.
29. Ghia P, Guida G, Stella S, et al. The pattern of CD38 expression defines a distinct sunset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003;101:1262-9.
30. Brooks SC III, Kazmer S, Levin AA, Yen A. Myeloid differentiation and RB phosphorylation changes in HL-60 cells induced by RAR- and RXR-selective retinoic acid analogs. Blood 1996;87:227-37.
31. Reiterer G, Yen A. Platelet-derived growth factor receptor regulates myeloid and monocytic differentiation of HL-60 cells. Cancer Res 2007;67:7765-72.
32. Wightman J, Roberson MS, Lamkin TJ, Varvayanis S, Yen A. Retinoic acid-induced growth arrest and differentiation: retinoic acid up-regulates CD32 (FcγRII) RII) expression, the ectopic expression of which retards the cell cycle. Mol Cancer Ther 2002;1:493-506.
33. Bhaumik SR. Analysis of in vivo targets of transcriptional activators by fluorescence resonance energy transfer. Methods 2006;40:353-9.
34. Dikic I, Szymkiewicz I, Soubeyran P. Cbl signaling networks in the regulation of cell function. Cell Mol Life Sci 2003;60:1805-27.
35. Hamilton E, Miller KM, Helm KM, Langdon WY, Anderson SM. Suppression of apoptosis induced by growth factor withdrawal by an oncogenic form of c-Cbl. J Biol Chem 2001;276:9028-37.
36. Dikic I, Giordano S. Negative receptor signaling. Curr Opin Cell Biol 2003;15:128-35.
37. Thien CB, Langdon WY. Cbl: many adaptors to regulate protein tyrosine kinase. Nat Rev Mol Cell Biol 2001;2:294-307.
38. Pennock S, Wang Z. A tale of two Cbls: interplay of c-Cbl and Cbl-b in epidermal growth factor receptor downregulation. Mol Cell Biol 2008;28:3020-37.
39. Qu X, Liu Y, Ma Y, Zhang Y, Li Y, Hou K. Up-regulation of the Cbl family of ubiquitin ligase is involved in ATRA and bufalin-induced cell adhesion but not cell differentiation. Biochem Biophys Res Commun 2008;267:183-9.
40. Kenae MM, Revero-Lezcano OM, Mitchell JA, Robbins KC, Lipkowitz S. Cloning and characterization of cbl-b: a SH3 binding protein with homology to the c-cbl proto-oncogene. Oncogene 1995;10:2367-77.
41. Jacob C, Cottrell GS, Gehringer D, Schmidlin F, Grady EF, Bunnett NW. c-Cbl mediates ubiquitination, degradation, and down-regulation of human protease-activated receptor 2. J Biol Chem 2005;280:16076-87.
42. Feshchenko EA, Langdon WY, Tsygankov AY. Fyn, Yes, and Syk phosphorylation sites in c-Cbl map to the same tyrosine residues that become phosphorylated in activated T cells. J Biol Chem 1998;273:8323-31.
43. Donovan JA, Wange RL, Langdon WY, Samelson LE. The protein product of the c-cbl protooncogene is the 120-kDa tyrosine-phosphorylated protein in Jurkat cells activated via the T cell antigen receptor. J Biol Chem 1994;260:22921-4.
44. Visser GD, Lill NL. The Cbl RING finger C-terminal flank controls epidermal growth factor receptor fate downstream of receptor ubiquitination. Exp Cell Res 2005;311:281-93.
45. Thien CB, Walker F, Langdon W. Ring finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation. Mol Cell 2001;7:355-65.